TrialThe Lancet. Infectious diseases2015

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Angela Huttner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.